Krystal Biotech (KRYS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
3 Apr, 2026Voting matters and shareholder proposals
Election of two Class III directors: Krish S. Krishnan and Christopher Mason, with board recommendation to vote in favor.
Ratification of KPMG LLP as independent registered public accounting firm for fiscal year ending December 31, 2026, recommended for approval.
Advisory approval of named executive officer compensation, with board recommendation to vote in favor.
Approval of Non-Employee Director Compensation Policy, recommended by the board.
Provision for other business to be addressed as may properly come before the meeting.
Board of directors and corporate governance
Nominees for Class III director positions are Krish S. Krishnan and Christopher Mason.
Executive compensation and say-on-pay
Advisory vote on the compensation of named executive officers is included as a proposal.
Separate proposal to approve the Non-Employee Director Compensation Policy.
Latest events from Krystal Biotech
- KB407 achieved robust, safe CFTR delivery and expression in CF lungs, enabling registrational trials.KRYS
Study Update9 Jul 2026 - KB301 showed durable, meaningful wrinkle reduction and safety, advancing to Phase 2 for décolleté.KRYS
Study Result8 Jul 2026 - KB408 and KB407 show strong safety, efficient lung gene delivery, and support for accelerated development.KRYS
Status Update8 Jul 2026 - Robust revenue, global expansion, and a deep gene therapy pipeline drive growth and innovation.KRYS
Corporate presentation25 May 2026 - Global expansion and pivotal pipeline progress set the stage for a transformative 12-24 months.KRYS
Bank of America Global Healthcare Conference 202619 May 2026 - All proposals, including director elections and compensation policies, were approved.KRYS
AGM 202615 May 2026 - Q1 2026 revenue and profit surged, with strong margins and major clinical milestones ahead.KRYS
Q1 20264 May 2026 - Global launches and pipeline advances drive growth, with key milestones expected in 2026.KRYS
44th Annual J.P. Morgan Healthcare Conference15 Apr 2026 - Proxy covers director elections, auditor ratification, pay, and new director compensation policy.KRYS
Proxy filing3 Apr 2026